Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: Long-term outcome

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 6, 2002, Pages 326-333

  Elias, Anthony D ^a   Skarin, Arthur T ^a   Richardson, Paul ^a   Ibrahim, Joseph ^a   McCauley, Mary ^a   Frei III, Emil ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Hematopoietic stem cell support; Phase II; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETANIDAZOLE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; STEROID; VINCRISTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLICATION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HUMAN; INFECTION; LIVER TOXICITY; LONG TERM CARE; LUNG SMALL CELL CANCER; MALE; METABOLIC DISORDER; METASTASIS; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL BLOOD STEM CELL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; SKULL IRRADIATION; SMALL CELL CARCINOMA; STEM CELL; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REMISSION; SURVIVAL; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036066568     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12108918     Document Type: Article

References (38)

1. Cancer statistics, 2000
2. Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome
3. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer
4. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants
5. Intensive chemotherapy of small cell bronchogenic carcinoma
6. Treatment of extensive stage small cell bronchogenic carcinoma: Effects of variation in intensity of induction chemotherapy
7. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
8. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: Minor improvements in rate of remission and survival
9. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer
10. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
11. Phase III study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (G-CSF) versus standard chemotherapy in extensive stage small cell lung cancer (SCLC)
12. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Council multicentre randomized trial
13. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study
14. Intensive combined modality therapy for limited stage small cell lung cancer
15. Randomised phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoietic progenitors in whole blood in small cell lung cancer (SCLC)
16. Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: An EBMT study
17. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy
18. Phase I study of high-dose ifosfamide, carboplatin, and etoposide with autologous hematopoietic stem cell support
19. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide and autologous hematopoietic stem cell support
20. Nonparametric estimation from incomplete observation
21. Planning the size and duration of a clinical trial studying the time to some critical event
22. A multiple testing procedure for clinical trials
23. Dose intensive therapy in lung cancer
24. Dose intensive therapy for limited stage small cell lung cancer: Long-term outcome
25. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer
26. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood
27. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation
28. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody
29. Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodies
30. Bone marrow metastases in small cell lung cancer: Detection with magnetic resonance imaging and monoclonal antibodies
31. Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen
32. Detection of bone marrow metastases in small cell lung cancer patients
33. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
34. Clinical applications of immunocytochemistry in the monitoring of the bone marrow in small cell lung cancer (SCLC)
35. Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer
36. CD34-selected peripheral blood progenitor cell (PBPC) support in high-dose therapy of small cell lung cancer (SCLC): Use of a novel detection method for minimal residual tumor (MRT)
37. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system